Makoto Maemondo.

Makoto Maemondo, M.D more ., Ph.D., Akira Inoue, M.D., Ph.D., Kunihiko Kobayashi, M.D., Ph.D., Shunichi Sugawara, M.D., Ph.D., Satoshi Oizumi, M.D., Ph.D., Hiroshi Isobe, M.D., Ph.D., Akihiko Gemma, M.D., Ph.D., Masao Harada, M.D., Ph.D., Hirohisa Yoshizawa, M.D., Ph.D., Ichiro Kinoshita, M.D., Ph.D., Yuka Fujita, M.D., Ph.D., Shoji Okinaga, M.D., Ph.D., Haruto Hirano, M.D., Ph.D., Kozo Yoshimori, M.D., Ph.D., Toshiyuki Harada, M.D., Ph.D., Takashi Ogura, M.D., Masahiro Ando, M.D., Ph.D., Hitoshi Miyazawa, M.S., Tomoaki Tanaka, Ph.D., Yasuo Saijo, M.D., Ph.D., Koichi Hagiwara, M.D., Ph.D., Satoshi Morita, Ph.D., and Toshihiro Nukiwa, M.D., Ph.D.1,2 Gefitinib can be an orally administered tyrosine kinase inhibitor of the epidermal growth factor receptor .3,4 In subsequent phase 3 trials, the noninferiority of gefitinib in comparison with docetaxel regarding overall survival was shown in one study 5 however, not another .6 Meanwhile, clinical and demographic factors such as for example Asian race, female sex, nonsmoking status, and adenocarcinoma were shown to be predictive of the efficacy of gefitinib, warranting a big comparative trial in which patients were selected relative to these factors.10,11 Therefore, we hypothesized that selecting sufferers on the basis of EGFR mutations rather than clinical factors would result in a population with a larger sensitivity to gefitinib.

Neuropsychological data were available for 24 patients; essentially no changes were seen in intelligence or neuropsychological measurements. The remaining 4 patients were cognitively and behaviorally impaired to an extent that standardized assessment had not been possible, despite repeated attempts. Testing in many individuals was hampered by below-average intelligence as well as autism and various other behavioral disorders substantially. The appearance of facial angiofibromas was believed to have improved in 13 of 15 patients at 6 months, although comparisons were made in accordance with the previous visit rather than the baseline visit and the evaluations weren’t always undertaken by the same clinician.